NCT02711176View on ClinicalTrials.gov

Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 27, 2017

Study Completion Date

March 27, 2017

Conditions
Helicobacter Infection
Interventions
DRUG

Nexium

Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily

DRUG

Tinafas

Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily

DRUG

Tavanex

Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily

DRUG

Lanzol

Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily

DRUG

Klacid

Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily

DRUG

Iramox

Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily

Trial Locations (1)

6939177143

Ilam University of Medical Scienvc, Īlām

All Listed Sponsors
lead

Zahra Vahdat Shariatpanahi

OTHER